Oruka Therapeutics amends CEO & SVP employment agreements, revising severance terms

Oruka Therapeutics, Inc.

CEO Klein: outside CIC, severance = 12 months base salary + 30% time-based equity vesting. Within CIC, 1.5x base+bonus + full equity acceleration.
SVP Agarwal: outside CIC, 9 months base salary. Within CIC, 0.75x base+bonus + full equity acceleration and 9 months COBRA.
Agreements also provide full time-based equity acceleration upon death/disability for Klein.
Base salary ($600K for CEO) and target bonus (50% of base) remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.